Crohn´s disease correlates highly with mediators of osteoimmunology Abstract Purpose: In the context of osteoimmunology in Crohn's disease, an association was hypothesized among vitamin D and members of the TNF-α family, known as the RANK (receptor-activator of nuclear factor-κB)-RANK ligand-osteoprotegerin pathway.
Crohn´s disease-related bone loss is a serious comorbid condition characterized by varied and complex aetiology [1] . e risk factors can be related to patient genetics, the impact of the in ammatory processes per se, environmental factors and/or long-term corticosteroid therapy [2, 3] . e high incidence of bone disease and increasing evidence that Crohn´s disease (CD) a ects bone status in corticosteroid users and non-users suggest that bone metabolism is strongly a ected by the underlying in ammatory state [4] .
Vitamin D plays a well-known role in bone formation and mineralization via its signalling pathway. Recent ndings have revealed that vitamin D also acts as an important regulator of immune system function. e immunomodulatory e ects of vitamin D, by down-regulating the T helper-1-driven immune response, suggest its plausible role in autoimmune disorders [5, 6] . Several lines of evidence have implicated vitamin D in deregulated immune response, known as the main characteristic of in ammatory bowel disease (IBD). Firstly, there are epidemiological reports of subclinical vitamin D de ciencies in IBD patients, measured by the precursor metabolite 25-hydroxyvitamin D3 which is the major circulating form of vitamin D [7] [8] [9] [10] [11] [12] . Secondly, numerous studies using various animal models have suggested that vitamin D signalling via the vitamin D receptor (VDR) plays an important role in the pathophysiology of the immune system in IBD [13] [14] [15] [16] [17] . Finally, experiments on immune-cell populations and in ammatory mediators have made substantial progress in understanding the mechanisms of vitamin D immunomodulatory e ects [18] [19] [20] [21] .
It is becoming evident that the vitamin D signalling pathway is shared between the immune and bone systems [22, 23] .
e interplay between these two systems is termed osteoimmunology. In the context of osteoimmunology in CD, we hypothesized that there is an association between vitamin D status and members of the TNF-α family: RANK (receptor activator of nuclear factor !B), RANK-ligand (RANKL) and osteoprotegerin (OPG). ese three TNF-α family members are involved in both the osteoclastogenesis and inate immune response [24] [25] [26] ; therefore, the main objectives of the present study were i) to evaluate serum concentrations of 25(OH)D3 and free soluble RANKL and OPG levels in newly diagnosed and long-standing Crohn´s patients and ii) to correlate these values with proin ammatory cytokines -biochemical markers of bone turnover and bone mineral density (BMD) for predicting metabolic bone disease in Crohn´s patients.
Methods
Patients e precursor metabolite, 25-hydroxyvitamin D 3 , was measured in 95 subjects either with long-standing (n=80) or newly diagnosed and previously untreated (n=15) CD. e diagnosis of CD was based on clinical, radiological and endoscope ndings, and was veri ed by histological ndings of the mucosal biopsy. Patients with other diseases or conditions that may inuence bone mass loss (hyperthyroidism, hyperparathyroidism, malignant diseases and postmenopausal women) were excluded. Upon study entry, bone status was measured by dualenergy x-ray absorptiometry and blood was sampled on the same day. Prior to bone density measurements, data were collected on patient age, sex, weight, height, location and disease duration, current medications, menstrual pattern in women, and history of intestinal resection and previous fractures. Of the 80 patients with long-standing CD, 22 had disease duration over 10 years and another ve patients had duration of over 20 years. According to the Montreal classi cation of disease location, upon diagnosis there were 31 patients in the L1 group, 16 in L2 and 42 in L3 (ileocolitis). Data are lacking for six patients. Among the previously diagnosed patients (n=80), 22 had undergone surgery, 10 for small bowel resection and another seven for large bowel resection. Another ve patients had combined small and large bowel resection at least once.
e group of newly diagnosed and previously untreated CD (n=15) had mild and moderate disease activity according to the CDAI and CRP levels.
Patients were divided into two groups according to corticosteroid therapy: never used and on therapy. If corticosteroid therapy was indicated, it was initiated at dose of 0.75mg/kg daily and then tapered o . Of the 80 patients with longstanding CD, 39 had been treated with steroids over a two month period at least once in their course of the disease. For the remainder of the 41 patients in the previously diagnosed group (n=80), there were no reliable data on steroid consumption and they could not therefore be considered as a steroid naïve group. With regard to steroid treatment, 31 previously diagnosed patients had received treatment with azathioprine, two with methotrexate and 16 had an overlap in both the steroid and azathioprine groups. ree years prior to this study, ve patients with perianal disease were treated in a clinical trial with in iximab for remission induction (application of three doses) and, without maintaining remission (if achieved), with anti-TNF therapy.
Laboratory data included complete blood count, basic biochemistry and speci c parameters such as free soluble Turk & Turk. Vitamin D and osteoimmunology in Crohn's disease RANKL, OPG, TNF-α, IL-6, osteocalcin and C-telopeptide levels. Body mass index (BMI) was calculated (kg/m 2 ). For newly diagnosed and untreated patients, the blood test and data on 25(OH)D3, OPG, sRANKL, IL-6 and TNFα were obtained during their rst hospitalization and before any treatment. For other patients, blood samples were taken upon their rst admission to this hospital.
To obtain a control group of healthy individuals that was age-sex matched to the CD-patients study group, 30 healthy volunteers (median age 33.5, range 21-45 years) who were not on medication or su ering from conditions a ecting bone density and did not have any known disease were selected. e local reference population was recruited from hospital personnel and their friends. As Croatia is a Mediterranean country with high levels of sunlight, and there was no reason to question vitamin D levels in the standard population.
Patients with ulcerative colitis (n=30) had a di erent disease duration and were considered as second control group. A total of 21 patients with proctitis / le sided colitis and nine with extensive colitis according to Montreal classi cation were included. None of the patients were on anti-TNFs or taking vitamin D supplements. In the groups, 12 and seven patients, respectively, were treated with steroids over a two-month period, at least once in their course of the disease. No signi cant di erences in 25(OH)D3 levels were found between the steroid users and non-users.
Ethics
e Hospital Ethics Committee approved the study protocol, and informed written consent was obtained from each subject before entering the study.
Bone Status Assessment
e lumbar spine (L1-L4) and total hip BMD was measured by absorptiometry (DXA) using a Delphi W (S/N 700483) instrument (Hologic, Inc., Waltham, , USA). BMD measurements were converted into T-scores re ecting the number of standard deviations below the mean for a young healthy population, and Z-scores re ecting the number of standard devia- tions below the mean for age-matched controls (database provided by the manufacturer). According to the International Society for Clinical Densitometry -2007 ISCD O cial Positions, a Z-score ≤ -2 SD is de ned as "below the expected range for age". A reduced BMD was considered for Z-scores ≤ -1 SD.
Vitamin D measurement
For the diagnosis of vitamin D de ciency, the precursor metabolite 25-hydroxyvitamin D3 was measured by the ELISA test purchased from Immunodiagnostik AG (Bensheim, Germany). e assay utilizes a competitive ELISA technique with a selected monoclonal antibody recognizing 25(OH)D3. Expected values given by the manufacturer are as follows: seriously decient <30 nmol/l, de cient 30-75 nmol/l and adequately supplied 75 nmol/l.
Cytokine Assay e sera (aliquots in separate vials stored at -80°C) were assayed for the concentrations of tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6). Serum levels of cytokines were determined using commerciallyavailable high sensitivity ELISAs according to manufacturer's instructions. TNF-α, IL-1β and IL-6 were purchased from R&D Systems (Minneapolis, MN, USA). All assays employed the quantitative sandwich-enzyme immunoassay technique.
e minimum detectable limits were as follows: TNF-α 0.12 pg/ml, IL-1β <0.1 pg/ml, and IL-6 0.039 pg/ml. Each sample was measured in duplicate.
RANK-ligand and Osteoprotegerin Measurements
Commercially-available speci c ELISAs were used according to the manufacturer's instructions (Biomedica GmbH, Vienna, Austria) to determine serum concentrations of soluble RANKligand (sRANKL) and OPG. It should be noted that the ELISA method used for RANKL measurements primarily detects free, unbound sRANKL, not the RANKL-OPG complex. Free, unbound sRANKL is the biologically active form of RANKL, and only the unbound state was measured in this study. e low detection limit of the OPG assay was 2.8 pg/ml and that of free sRANKL 1.6 pg/ml. Each sample was measured in duplicate.
Normative values for free sRANKL and OPG were determined in a control group of 30 healthy volunteers matched by age and sex to the study group of CD patients. e established own normal value (mean, 95% CI) was 5.7 (4.7-6.6) pg/ml for free sRANKL and 52 (44-60) pg/ml for OPG.
Biochemical Parameters of Bone Turno er
Serum tests for bone formation and resorption included osteocalcin and collagen type I C-terminal crosslink. Serum osteocalcin was measured by the Immulite " Osteocalcin (Diagnostic Products Corporation, Los Angeles, CA, USA) immunoassay using a chemiluminescent substrate and reference range for healthy adults of 3.1-13.7 ng/ml.
Collagen type I C-terminal crosslink, a breakdown product of type I collagen secreted to the bloodstream, was measured by a competitive CrossLabs ELISA (Nordic Bioscience Diagnostics A/S, Herlev, Denmark). 
Statistical analysis
Variables with a skewed distribution (i.e., 25 (OH)D3, RANKL, OPG, IL-6, TNF-α, CRP, osteocalcin and BMI) were logarithmically transformed prior to further analyses. Di erences between continuous variables were evaluated by ANOVA or Mann-Whitney U test, as appropriate. Categorical variables were expressed as percentages and compared using the chisquare test. Linear regression analysis was used to examine the extent to which 25(OH)D3 levels were associated with proinammatory cytokines, RANKL, OPG, biochemical markers of bone turnover, as well as with bone mineral density (BMD) and z-scores. Each variable that showed an independent and signi cant correlation in the univariate correlation analyses were additionally tested by multiple regression analysis conducted by a stepwise model. Logistic regression analysis was used to identify the predictors of bone disease. In this study, bone disease was set as a dependent variable, and the independent variables used were those with previous statistical signicance and those with proven clinical relevance.
Results

Vitamin D and Crohn!s disease
Adequate 25(OH)D3 levels (>75 nmol/l) were observed in only 9% of the CD patients in the study group (n=95). Suboptimal 25(OH)D3 levels were observed in 91% of participants and 40% had a serious de ciency (<30 nmol/l). Patients with inadequate 25(OH)D3 levels tended to be older (although this was not signi cant) and had a longer disease duration (p=0.003) ( Table 1) . ere was no signi cant di erence in 25(OH)D3 levels between CD patients (n=95) and those with ulcerative colitis (n=30). Interestingly, 75% of newly diagnosed CD patients (n=15) showed a serious de ciency of 25(OH)D3 (<30 nmol/l) at diagnosis. e prevalence of 25(OH)D3 de ciency in corticosteroid users and non-users was not statistically signi cant (p=0.384). Table 1 shows the basic characteristics and biochemical markers in the three subgroups of CD patients according to 25 (OH)D3 level. Analysis revealed that the signicantly increased production of the osteoclastical factors, free sRANKL (p=0.014), and the proin ammatory cytokines TNF-α (p=0.015) and IL-6 (p=0.029) were associated with 25(OH)D3 de ciency. Table 2 shows the results of univariate and multivariate regression of circulatory 25(OH)D3 determinants. Proin ammatory free sRANKL and IL-6 were associated with 25(OH)D3 levels inversely and this association was highly signi cant (Fig 1) . In the multivariate model using stepwise regression, a signi cant association was con rmed between the proin ammatory cytokines and regulatory molecules of osteoclastogenesis, (as independent predictors), and 25(OH)D3; free sRANKL (regression coe cient β=-0.24, p=0.038), IL-6 (β=-0.412, p=0.003) and TNF-α (β=0.249, p=0.036) ( Table 2) . 25 (OH)D3 insu ciency was additionally analysed as the logistic function of the explanatory variables. In this model, the set of proin ammatory parameters (OPG, free sRANKL, IL-6, CRP and TNF-α) were identi ed as signi cant (p=0.015) independent contributors of 25(OH)D3 insu ciency, whereas the variables of bone turnover, bone status assessment and patients basic characteristics (age, disease duration, BMI and steroid treatment) were not relevant.
Vitamin D in in ammatory conditions
Vitamin D relationship to bone status
CD patients (n=68) with low BMD (mean lumbar z-score, -1.88, total hip z-score, -1.33) had a mean level of 25 ciency, whereas patients with normal BMD (n=27) had higher levels of 49±28 nmol/l, though this is still within the range of inadequate levels (ANOVA p=0.004). e analysis showed a signi cantly higher production of IL-6 (p=0.008), TNF-α (p=0.007) and free sRANKL (p=0.046) in patients with established bone disease (Figure 2 ). e logistic regression model was used to analyse the predicting outcome of bone disease (dependent variable). e level of 25(OH)D3, as an independent variable, was classi ed as adequately supplied, de cient or seriously de cient. e chi-square result (6.78) for the di erence between the intercept and current model was highly signi cant (p<0.009), with an odds ratio=2.66 (range 6.8) and constant B0= -1.28. us, the low 25(OH)D3 is a signi cant predictor of the likelihood of bone disease. In the multivariable analysis adjusted for several confounding factors, 25(OH)D3 levels, together with free sRANKL, IL-6, TNF-α, OPG, and steroid therapy, were independently-associated with a likelihood of bone disease [odds ratio (range): 1.04(6.24); 1.07(2.63); 1.22(4.95); 1.0(6.02); 3.17(3.17), respectively, p=0.0001]. Sixteen (17%) of the study patients reported fractures a er CD diagnosis. 25 (OH)D3 insu ciency per se, was not found to be associated with the incidence of bone fractures. None of the patients or control group received bisphosphonates, vitamin D or calcium supplements, with the exception of three patients with long standing CD and established osteoporosis, who were treated with bisphosphonates, vitamin D and calcium supplements. Two of these patients reported bone fractures prior to initiating bisphosphonate treatment. ese subjects were included in the study as there was no impact on results, even when they were excluded from the study.
Discussion
e present study is focused on the association between 25-hydroxyvitamin D 3 levels and objective osteoimmunology markers, which may aid in better predicting bone disease in IBD. Serum 25-hydroxyvitamin D 3 levels were used to evaluate vitamin D status in study patients. 25 (OH)D3 is the major circulating form of vitamin D and numerous studies have proven it to be the best indicator for monitoring vitamin D status [7, 35, 36, 37] . Although 1,25(OH) 2 D 3 represents the biologicallyactive form of vitamin D, its level is regulated by the parathyroid hormone, calcium and phosphorus levels, and its measurement does not re ect vitamin D status [7] . e Clinical Guidelines of the Endocrine Society suggest the measurement of serum 25-hydroxyvitamin D levels by a reliable assay as the initial diagnostic test in patients at risk for vitamin D deciency [35) . e prevalence of 25(OH)D3 de ciencies in the study group was relatively high. A total of 90% of Crohn's disease patients had suboptimal concentrations of 25 Fig 1A) and in ammatory marker ship was inversely signi cant; 25(OH) D3 and free sRANKL (r= -0.3, ues were used.
prevalence of 22-70% [9, 27] , although a de ciency prevalence of up to 91% was also observed [28] . Given the present and previous ndings regarding the association between vitamin D de ciency and disease activity, this may re ect the fact that all patients in this study were under hospital treatment and experiencing a graver form of the disease than the general CD population.
e ndings of this study show a particularly high association among low 25(OH)D3 levels and high levels of in ammatory markers and the regulatory factor of osteoclastogenesis.
e results revealed the signi cantly increased production of osteoclastical free soluble RANKL and proin ammatory cytokines TNF-α and IL-6 to be associated with a serious deciency or suboptimal levels of 25(OH)D3. In fact, this relationship was characterized by an inverse correlation. Osteoclastically-active sRANKL, its receptor RANK and osteoprotegerin share the molecular pathway that underlie the skeletal and immune systems [22] . In in ammatory states, both B-and T-cells produce RANKL. We reasoned that the local production of a cascade of proin ammatory cytokines and RANKL biogenesis was not limited to the induction of intestinal inammation, but might be involved in the activation of bone metabolism [26, 29] . Our clinical data are in good agreement with the experimental observations, in which vitamin D deciency induces RANKL-mediated osteoclastogenesis [30] . A serious de ciency of 25(OH)D3 was found in 75% of treatment naïve Crohn's disease patients at diagnosis, and this observation was accompanied by reduced bone mineral density. Decreased 25(OH)D3 in the systemic circulation of naïve Crohn's disease patients has been reported elsewhere [11] ; however, it is unclear whether 25 (OH)D3 de ciency plays a causative role in pathogenesis or is a consequence of intestinal malabsorption.
e knowledge of the role of vitamin D in immunomodulation in IBD has been expanded and a body of evidence has documented its implication in disease pathogenesis [31, 32] .
Immunologically, CD appears to be a result of deregulation of innate intestinal immunity. In this deregulation process, NOD2 encodes a protein that recognizes muramyl dipeptide, the lysosomal breakdown product of bacterial peptidoglycan [33] . e protein, NOD2, has been associated with numerous regulatory roles in the mucosal immune system. e NOD2/ CARD15/IBD gene is the locus associated with the strongest risk of development of CD and major NOD2 mutations that encode proteins incapable of recognizing muramyl dipeptide [34] . It is known that all immune system cells can express the vitamin D receptor, a member of the nuclear receptor family of ligand-regulated transcription factors. Recent data indicate that the active form of vitamin D (1,25-dihydroxyvitamin D3) acts as a VDR-ligand in promoting transcription of the NOD2 gene, thus highlighting an important link between the vitamin D axis and pathogenesis of IBD [18, 31] . e present study has several limitations. is was a crosssectional study with a heterogeneous population of 95 Crohn`s patients, with a limited number of 15 newly-diagnosed patients who had not previously received treatment. Half of the 80 patients were diagnosed with CD in other hospitals and referred to our institution later in the course of the disease; therefore, medical records and the initial disease activity grading were absent for some patients. As Crotia is a Mediterranean country with plenty of sun, the focus was not placed on dietary intake of vitamin D. Periodic, though not necessarily daily, exposure to sunlight should be su cient to prevent vitamin D deciency. Changes in the patient's dietary intake of food rich in calcium or vitamin D would be di cult or impossible to track. Regardless of the limitations, we can conclude that vitamin D de ciency re ects CD itself rather than the background population in Croatia.
Metabolic bone disease is a well-recognised complication of CD. e pivotal role of vitamin D in skeletal homeostasis and its interplay with the osteoimmunology pathway is believed to a ect bone status. e clinical data presented here show very good agreement between low levels of 25(OH)D3 and low BMD z-scores and these 25(OH)D3 values correlated inversely with elevated osteoimmunology markers. e multivariate analysis showed that 25(OH)D3 de ciency, together with elevated levels of free soluble RANKL, IL-6, TNF-α, OPG, and steroid therapy, was an independent predictor of bone disease outcomes. Our present results strongly suggest that 25(OH)D3 de ciency, accompanying an in ammatory state in CD, is a high risk condition for metabolic bone disease.
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